Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Characterizing foam cells in human atherosclerotic lesions using a new multiplex imaging platform.

EF 2022-23

Résumé
Characterizing cells in human atherosclerotic arteries using a novel imaging technology. Heart attacks and strokes are the leading killers around the world. Most of them are caused by atherosclerosis: a plaque made of diseased cells and accumulated cholesterol in the artery wall. The most popular therapy used to prevent heart attacks, statin, is designed to help diseased cells remove the extra cholesterol from the artery wall. Previous studies suggested that some cells may not respond well to statin. Yet, traditional technologies cannot determine what these cells are and why they do not respond to statin. As a result, we don’t know how to design therapies to specifically target these cells and improve treatment outcomes for patients. In my project, I will address this knowledge gap using a novel imaging technology. This tool can define the identity and features of many cell types simultaneously. I have tailored this new imaging technology to work with plaques donated by patients with atherosclerosis disease, the ideal model for studying human disease. I expect to find that a type of commonly found diseased cells cannot efficiently remove cholesterol. Therefore, we need to design drugs to specifically treat this cell type. Such treatment will benefit patients with atherosclerosis by slowing disease progression and lowering the risk of heart attacks and strokes. This is the first time a new imaging technology being applied to human plaques to overcome the limitations of previous research.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
486461
Name
Elishaev Maria
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterizing foam cells in human atherosclerotic lesions using a new multiplex imaging platform.
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Atherosclerosis; Cholesterol Efflux; Foam Cells; Vascular Biology
Abstract
Characterizing cells in human atherosclerotic arteries using a novel imaging technology. Heart attacks and strokes are the leading killers around the world. Most of them are caused by atherosclerosis: a plaque made of diseased cells and accumulated cholesterol in the artery wall. The most popular therapy used to prevent heart attacks, statin, is designed to help diseased cells remove the extra cholesterol from the artery wall. Previous studies suggested that some cells may not respond well to statin. Yet, traditional technologies cannot determine what these cells are and why they do not respond to statin. As a result, we don’t know how to design therapies to specifically target these cells and improve treatment outcomes for patients. In my project, I will address this knowledge gap using a novel imaging technology. This tool can define the identity and features of many cell types simultaneously. I have tailored this new imaging technology to work with plaques donated by patients with atherosclerosis disease, the ideal model for studying human disease. I expect to find that a type of commonly found diseased cells cannot efficiently remove cholesterol. Therefore, we need to design drugs to specifically treat this cell type. Such treatment will benefit patients with atherosclerosis by slowing disease progression and lowering the risk of heart attacks and strokes. This is the first time a new imaging technology being applied to human plaques to overcome the limitations of previous research.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Elishaev, Maria
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~